The WldS mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo

Journal of Neurochemistry

Volumn 113, Issue 3, 2010, Pages 683-691

  Cheng, Hsiao Chun ^a   Burke, Robert E ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Apoptosis; Axon; Axonopathy; Parkinson's disease; Wallerian

Indexed keywords

GENE PRODUCT; PROTEIN WLDS; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC SYSTEM; FEMALE; GENE MUTATION; IN VIVO STUDY; MALE; MOUSE; NERVE FIBER DEGENERATION; NERVE INJURY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; AXONS; AXOTOMY; DOPAMINE; FEMALE; GREEN FLUORESCENT PROTEINS; HYDROXYDOPAMINES; IMMUNOHISTOCHEMISTRY; MEDIAL FOREBRAIN BUNDLE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MUTATION; NEOSTRIATUM; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; PROMOTER REGIONS, GENETIC; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

MUS; WALLERIA;

EID: 77950648666     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06632.x     Document Type: Article

References (33)

1. Beirowski B., Babetto E., Gilley J., Mazzola F., Conforti L., Janeckova L., Magni G., Ribchester R. R. Coleman M. P. (2009) Non-nuclear Wld(S) determines its neuroprotective efficacy for axons and synapses in vivo. J. Neurosci. 29, 653 668.
2. Chen X., Rzhetskaya M., Kareva T., Bland R., During M. J., Tank A. W., Kholodilov N. Burke R. E. (2008) Antiapoptotic and trophic effects of dominant-negative forms of dual leucine zipper kinase in dopamine neurons of the substantia nigra in vivo. J. Neurosci. 28, 672 680.
3. Cheng H. C., Oo T. F., Kareva T., Rzhetskaya M., Wang C., During M. J., Kobayashi K., Okano H., Kholodilov N. Burke R. E. (2008) Akt/PKB inhibits retrograde axonal degeneration in the nigro-striatal dopaminergic pathway in vivo. Abstr. Soc. Neurosci. 741.7.
4. Cheng H. C., Ulane C. M. Burke R. E. (2009) Clinical progression in Parkinson's disease and the neurobiology of axons. Ann Neurol, 2010, in press.
5. Coleman M. (2005) Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 6, 889 898.
6. Coleman M. P. Perry V. H. (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 25, 532 537.
7. Eberhardt O., Coelln R. V., Kugler S. et al. (2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20, 9126 9134.
8. El-Khodor B. F. Burke R. E. (2002) Medial forebrain bundle axotomy during development induces apoptosis in dopamine neurons of the substantia nigra and activation of caspases in their degenerating axons. J. Comp. Neurol. 452, 65 79.
9. Ellis R. E., Yuan J. Horvitz H. R. (1991) Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 7, 663 698.
10. Fearnley J. M. Lees A. J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283 2301.
11. Greffard S., Verny M., Bonnet A. M., Beinis J. Y., Gallinari C., Meaume S., Piette F., Hauw J. J. Duyckaerts C. (2006) Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584 588.
12. Hasbani D. M. O'Malley K. L. (2006) Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp. Neurol. 202, 93 99.
13. Hoopfer E. D., McLaughlin T., Watts R. J., Schuldiner O., O'Leary D. D. Luo L. (2006) Wlds protection distinguishes axon degeneration following injury from naturally occurring developmental pruning. Neuron 50, 883 895.
14. Hornykiewicz O. (1998) Biochemical aspects of Parkinson's disease. Neurology 51, S2 S9.
15. Hotchkiss R. S., Strasser A., McDunn J. E. Swanson P. E. (2009) Cell death. N. Engl. J. Med. 361, 1570 1583.
16. Jeon B. S., Jackson-Lewis V. Burke R. E. (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 4, 131 137.
17. Kerschensteiner M., Schwab M. E., Lichtman J. W. Misgeld T. (2005) In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat. Med. 11, 572 577.
18. Lee C. S., Samii A., Sossi V. et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47, 493 503.
19. Li Y., Liu W., Oo T. F. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826 828.
20. Lunn E. R., Perry V. H., Brown M. C., Rosen H. Gordon S. (1989) Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur. J. Neurosci. 1, 27 33.
21. Luo L. O'Leary D. D. (2005) Axon retraction and degeneration in development and disease. Annu. Rev. Neurosci. 28, 127 156.
22. Ma S. Y., Roytta M., Rinne J. O., Collan Y. Rinne U. K. (1997) Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J. Neurol. Sci. 151, 83 87.
23. Mack T. G., Reiner M., Beirowski B. et al. (2001) Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat. Neurosci. 4, 1199 1206.
24. Mi W., Conforti L. Coleman M. P. (2002) Genotyping methods to detect a unique neuroprotective factor (Wld(s)) for axons. J. Neurosci. Methods 113, 215 218.
25. Mi W., Beirowski B., Gillingwater T. H. et al. (2005) The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain 128, 405 416.
26. Raff M. C., Whitmore A. V. Finn J. T. (2002) Axonal self-destruction and neurodegeneration. Science 296, 868 871.
27. Ries V., Silva R. M., Oo T. F., Cheng H. C., Rzhetskaya M., Kholodilov N., Flavell R. A., Kuan C. Y., Rakic P. Burke R. E. (2008) JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J. Neurochem. 107, 1578 1588.
28. Sajadi A., Schneider B. L. Aebischer P. (2004) Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr. Biol. 14, 326 330.
29. Sauer H. Oertel W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6 hydroxydopamine a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401 415.
30. Sawamoto K., Nakao N., Kobayashi K. et al. (2001) Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. Proc. Natl Acad. Sci. USA 98, 6423 6428.
31. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F. Agid Y. (1989) Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann. Neurol. 26, 551 557.
32. Selkoe D. J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789 791.
33. Wang M. S., Fang G., Culver D. G., Davis A. A., Rich M. M. Glass J. D. (2001) The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann. Neurol. 50, 773 779.